Pfizer Inc. (PFE) Financials
Key financial figures for Pfizer Inc. (Q2 2026).
Pfizer grew Q2 2026 revenue 3% to $15.03 billion, posted a GAAP net loss on one-off items, and raised full-year revenue guidance by $500 million at the midpoint to $60.5-$62.5 billion. Revenue $15.03B (+3% YoY vs $14.65B in Q2 2025); adjusted diluted EPS $0.77 (vs $0.78 in Q2 2025) Reported (GAAP) diluted EPS was a loss of $(0.04) versus $0.51 a year ago, on a reported net loss of $(248)M versus net income of $2,910M in Q2 2025 Eliquis grew to $2.43B, the largest non-COVID product revenue driver in the release's SELECTED PRODUCT REVENUES table COVID franchise kept shrinking: Comirnaty fell to $261M (from $381M) and Paxlovid to $21M (from $427M) Full-year 2026 revenue guidance raised to $60.5-$62.5B (from $59.5-$62.5B); adjusted EPS guidance reaffirmed at $2.80-$3.00 The comp. On the outlook: Full-year 2026 revenue guidance raised by $500 million at the midpoint to $60.5-$62.5 billion (from $59.5-$62.5 billion); adjusted diluted EPS guidance reaffirmed at $2.80-$3.00. Figures are for Q2 2026, as Pfizer Inc. reported them.
- Revenue
- $15.0B
- Net Income
- -$237M
- EPS
- $-0.04
- Total Assets
- $201.1B
- Operating Cash Flow
- $835M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $15.0B | -$246M | -$0.04 | 31.3% | $302M |
| Q1 FY2026 | $14.5B | $2.7B | $0.47 | 27.9% | $2.2B |
| Q4 FY2025 | $17.6B | -$1.6B | -$0.29 | 21.01% | $4.5B |
| Q3 FY2025 | $16.7B | $3.5B | $0.62 | 21.32% | $4.0B |
| Q2 FY2025 | $14.7B | $2.9B | $0.51 | 24.4% | -$1.2B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | $1.36 | 24.67% | $9.1B |
| FY2024 | $63.6B | $8.0B | $1.41 | 25.91% | $9.8B |
| FY2023 | $59.6B | $2.1B | $0.37 | 8.89% | $4.8B |
Frequently asked questions
What was Pfizer Inc.'s revenue last quarter?
Pfizer Inc. reported revenue of $15.03 billion for Q2 FY2026, up 2.6% from the same period a year earlier.
Is Pfizer Inc. profitable?
Not in its most recent reported period. Pfizer Inc. reported a net loss of $246.0 million for Q2 FY2026, a net margin of -1.64% on revenue.
How has Pfizer Inc.'s margin trended?
Operating margin was 31.3% in Q2 FY2026, compared with 24.4% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Pfizer Inc. generate?
Pfizer Inc. generated free cash flow of $302.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Pfizer Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.